Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):120-129. doi: 10.1016/j.ijrobp.2024.02.056. Epub 2024 Mar 8.
To evaluate the diagnostic performance of diffusion-weighted imaging (DWI) in the 6-month interval post chemoradiation therapy (CRT) in determining persistent disease and whether persistent diffusion restriction on DWI at 6 months is associated with overall survival; and secondarily, to investigate the accuracy of pelvic lymph node assessment on T2-weighted imaging and DWI in the 6-month interval post CRT, in patients with squamous cell carcinoma of the anus.
This retrospective study included patients with squamous cell carcinoma of the anus who underwent CRT followed by restaging rectal MRI from January 2010 to April 2020, with ≥1 year of follow-up after CRT. DW images were qualitatively evaluated by 2 junior and 2 senior abdominal radiologists to determine anal persistent disease. The reference standard for anal persistent disease was digital rectal examination/endoscopy and histopathology. Diagnostic performance was estimated using sensitivity, specificity, negative predictive value, and positive predictive value. Survival outcomes were evaluated via Kaplan-Meier analysis, and associations between survival outcomes and DWI status were tested for significance using the log-rank test. Additionally, DW and T2-weighted images were evaluated to determine lymph node status.
Among 84 patients (mean age, 63 ± 10.2 years; 64/84 [76%] female), 14 of 84 (17%) had confirmed persistent disease. Interreader agreement on DWI between all 4 radiologists was moderate (Light's κ = 0.553). Overall, DWI had a sensitivity of 71.4%, specificity of 72.1%, positive predictive value of 34.5%, and negative predictive value of 92.5%. Patients with a negative DWI showed better survival than patients with a positive DWI (3-year overall survival of 92% vs 79% and 5-year overall survival of 87% vs 74%), although the difference did not reach statistical significance (P = .063). All patients with suspicious lymph nodes (14/14, 100%) showed negative pathology or decreased size during follow-up.
At 6 months post CRT, DWI showed value in excluding anal persistent disease. Persistent diffusion restriction on DWI was not significantly associated with overall survival. Pelvic nodal assessment on DWI and T2-weighted imaging was limited in predicting persistent nodal metastases.
评估弥散加权成像(DWI)在放化疗后 6 个月间隔期诊断持续性疾病的性能,并探讨 6 个月时 DWI 上持续弥散受限是否与总生存相关;其次,研究 T2 加权成像和 DWI 在放化疗后 6 个月间隔期评估肛门鳞癌患者盆腔淋巴结的准确性。
本回顾性研究纳入了 2010 年 1 月至 2020 年 4 月期间接受放化疗后行直肠 MRI 再分期的肛门鳞癌患者,所有患者在放化疗后均有≥1 年的随访。2 名初级和 2 名高级腹部放射科医生对 DW 图像进行定性评估,以确定肛门是否存在持续性疾病。肛门持续性疾病的参考标准为直肠指检/内镜和组织病理学。使用灵敏度、特异性、阴性预测值和阳性预测值评估诊断性能。通过 Kaplan-Meier 分析评估生存结果,并使用对数秩检验检验生存结果与 DWI 状态之间的关联。此外,评估 DW 和 T2 加权图像以确定淋巴结状态。
在 84 例患者中(平均年龄 63±10.2 岁;64/84[76%]为女性),14 例(17%)被证实存在持续性疾病。4 名放射科医生对 DWI 的读者间一致性为中度(Light's κ=0.553)。总体而言,DWI 的灵敏度为 71.4%,特异性为 72.1%,阳性预测值为 34.5%,阴性预测值为 92.5%。DWI 阴性的患者生存情况优于 DWI 阳性的患者(3 年总生存率为 92%比 79%,5 年总生存率为 87%比 74%),尽管差异无统计学意义(P=0.063)。所有可疑淋巴结患者(14/14,100%)在随访期间均表现为阴性病理或淋巴结缩小。
在放化疗后 6 个月时,DWI 在排除肛门持续性疾病方面具有价值。DWI 上持续弥散受限与总生存无显著相关性。DWI 和 T2 加权成像的盆腔淋巴结评估在预测持续性淋巴结转移方面存在局限性。